| answer text |
<p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible
government is to prepare for all eventualities, including ‘no deal’. On 23 August
2018, therefore, the Department wrote to all pharmaceutical companies that supply
the United Kingdom with prescription only or pharmacy medicines from, or via, the
European Union/European Economic Area, asking them to ensure they have a minimum of
six weeks’ additional supply in the UK, over and above their business as usual operational
buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since
then, we have received very good engagement from industry who share our aims of ensuring
continuity of medicines supply for patients is maintained and able to cope with any
potential delays at the border that may arise in the short term in the event of a
no-deal Brexit.</p><p> </p><p>We understand that statins are vitally important to
many people in this country. However, the Department recognises that through its medicines
supply contingency programme it is requesting sensitive commercial information from
pharmaceutical companies. To reassure participating companies, we have committed to
treating all information received confidentially, securely and to using it only for
the purposes of the Department’s programme. That means not introducing information
about a company, specific medicine or their supply routes into the public domain.</p>
|
|
